HLA-A2 restrictive epitope polypeptide of LMP2A protein source and purpose thereof

A technology of LMP2A264 and HLA-A2, applied in the direction of peptide/protein components, medical preparations with non-active ingredients, medical preparations containing active ingredients, etc., can solve the problem of patients who are prone to recurrence and metastasis, and cannot completely and effectively remove tumor cells , side effects and other issues
CN101643497AInactive Publication Date: 2010-02-10NANJING MEDICAL UNIV
0 Cites 9 Cited by

Patent Information

Authority / Receiving Office
CN · China
Current Assignee / Owner
NANJING MEDICAL UNIV
Publication Date
2010-02-10
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention discloses HLA-A2 restrictive epitope polypeptide of an LMP2A protein source, which is polypeptide LMP2A264 and comprises 9 amino acids in the positions of 264 to 272; the sequence is QLSPLLGAV. Mycobacteria heat shock protein 70 (HSP70) is expressed, identified and purified; a transgene animal model for evaluating EBV relevant polypeptide vaccine in vivo tests is established; the immune research on inducing EBV specific CTL inside and outside healthy volunteers and transgene rats for the new EBV epitope polypeptide LMP2A264 is systemically researched and the tumor prevention andthe tumor treating test of the polypeptide LMP2A264 on LMP2A positive solid tumors are evaluated, thereby proving that the polypeptide LMP2A264 can induce LMP2A specific cell toxic T lymphocyte reaction. Therefore, the polypeptide LMP2A264 can be applied to prepare medicaments for treating or preventing LMP2A positive solid tumors.
Need to check novelty before this filing date? Find Prior Art

Description

Technical field:

[0001] The invention relates to an HLA-A2 restricted epitope polypeptide derived from LMP2A protein and its application in the treatment and prevention of solid tumors Background technique

[0002] Epstein-Barr virus (EBV) is a member of the γ subfamily of the Herpesviridae family. It was first isolated from African childhood lymphoma by Epstein and Barr in 1964. About 95% of the world's people have been infected with EBV and become carriers. Nasopharyngeal carcinoma (NPC) is a malignant tumor derived from epithelial cells that is highly related to EBV infection, and is one of the common tumors in the head and neck. NPC occurs frequently in Southeast Asia and South China. The current incidence rate in Jiangsu is also increasing, with an average of 10 to 20 new cases per week, and about 960 new cases per year. Clinically, NPC cannot be treated with surgery, mainly through radiotherapy and chemotherapy, but this treatment method cannot completely and effecti...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More